A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder

Brief description of study

This trial is a phase 3, double-blind, placebo-controlled, randomized withdrawal maintenance trial of brexpiprazole in subjects who require adjunctive treatment of MDD designed to fulfill a post-marketing commitment to the US Food and Drug Administration (FDA). There is a paucity of data on long-term use of the combination of ADT and an antipsychotic drug.The trial will assess long-term benefit of continuation of adjunctive therapy in subjects who achieve a level of clinical stabilization.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Major depressive disorder, depression
  • Age: - 99 Years
  • Gender: All
Updated on 03 Mar 2022. Study ID: 831294

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center